• I have a longstanding interest in the cause and clinical expression of IgA nephropathy. Research collaboration with colleagues over my career has focused on the genetically determined influences on the pathogenesis and the autoimmune nature of the mechanisms of disease. These studies have shown that there are many regions in the human genome that affect the risk for development of IgA nephropathy. We have also proposed a four-hit hypothesis for the pathogenesis: galactose-deficient IgA1 is recognized by IgG or IgA that binds to its galactose-deficient hinge-region glycans to form circulating immune complexes, some of which deposit in the mesangium of glomeruli to induce injury. Subsequent studies from centers around the world have supported this hypothesis. This model now serves as the blueprint for testing new approaches to therapy that are more disease-specific.
    I also am a transplant nephrologist. The kidney transplant program at UAB is one of the busiest in the USA. I have a special interest in outcomes and co-morbidities, including changes in bone mineral metabolism, post-transplant erythrocytosis, and genetic influences on long-term survival.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Employment status at transplant influences ethnic disparities in outcomes after deceased donor kidney transplantationBMC Nephrology.  23. 2022
    2022 Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traitsNature Communications.  13. 2022
    2022 Associations between female birth sex and risk of chronic kidney disease development among people with HIV in the USA: A longitudinal, multicentre, cohort studyEClinicalMedicine.  53. 2022
    2021 Iga vasculitis with nephritis in adults: Histological and clinical assessmentJournal of Clinical Medicine.  10. 2021
    2021 Mesangioproliferative Kidney Diseases and Platelet-Derived Growth Factor–Mediated AXL PhosphorylationKidney Medicine.  3:1003-1013.e1. 2021
    2021 Pathogenesis of iga nephropathy: Current understanding and implications for development of disease-specific treatmentJournal of Clinical Medicine.  10. 2021
    2021 Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathyJournal of Autoimmunity.  118. 2021
    2021 IgA Nephropathy: An Interesting Autoimmune Kidney Disease: IgA NephropathyAmerican Journal of the Medical Sciences.  361:176-194. 2021
    2021 Impact of Subclinical Borderline Inflammation on Kidney Transplant OutcomesTransplantation Direct.  7:E663. 2021
    2020 Genome-wide association study for time to failure of kidney transplants from African American deceased donorsClinical Transplantation.  34. 2020
    2020 Persistent Disease Activity in Patients With Long-Standing Glomerular DiseaseKidney International Reports.  5:860-871. 2020
    2020 Leukemia Inhibitory Factor Signaling Enhances Production of Galactose-Deficient IgA1 in IgA Nephropathy.Kidney Diseases.  6:168-180. 2020
    2020 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and RationaleKidney International Reports.  5:278-288. 2020
    2020 Role of Epstein-Barr Virus in Pathogenesis and Racial Distribution of IgA NephropathyFrontiers in Immunology.  11. 2020
    2020 TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6–mediated pathways in IgA nephropathyKidney International.  97:340-349. 2020
    2020 Redefining the Influence of Ethnicity on Simultaneous Kidney and Pancreas Transplantation Outcomes: A 15-year Single-center ExperienceAnnals of Surgery.  271:177-183. 2020
    2019 Autoantibodies Specific for Galactose-Deficient IgA1 in IgA Vasculitis With NephritisKidney International Reports.  4:1717-1724. 2019
    2019 Health-related quality of life in glomerular diseaseKidney International.  95:1209-1224. 2019
    2019 CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular DiseaseAmerican Journal of Kidney Diseases.  73:218-229. 2019
    2019 Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1Journal of the American Society of Nephrology.  30:2017-2026. 2019
    2019 The emerging role of complement proteins as a target for therapy of IgA nephropathyFrontiers in Immunology.  10. 2019
    2018 Population Health, Ethnicity, and Rate of Living Donor Kidney TransplantationTransplantation.  102:2080-2087. 2018
    2018 Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN StudyKidney International Reports.  3:1373-1384. 2018
    2018 Secondary IgA nephropathyKidney International.  94:674-681. 2018
    2018 Aberrant Glycosylation of the IgA1 Molecule in IgA NephropathySeminars in Nephrology.  38:461-476. 2018
    2018 Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1–second gene interactionsKidney International.  94:599-607. 2018
    2018 Assay for galactose-deficient IgA1 enables mechanistic studies with primary cells from IgA nephropathy patients 2018
    2018 Apolipoprotein L1 and Chronic Kidney Disease Risk in Young Potential Living Kidney DonorsAnnals of Surgery.  267:1161-1168. 2018
    2018 Evaluation of potential living kidney donors in the APOL1 eraJournal of the American Society of Nephrology.  29:1079-1081. 2018
    2018 Life Expectancy for Patients From the Southeastern United States With IgA NephropathyKidney International Reports.  3:99-104. 2018
    2018 Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathyPLoS One.  13. 2018
    2017 Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysisNephrology Dialysis Transplantation.  32:2079-2089. 2017
    2017 Apolipoprotein L1 Gene Effects on Kidney TransplantationSeminars in Nephrology.  37:530-537. 2017
    2017 Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage 2017
    2017 Effect of Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk IndexAmerican Journal of Transplantation.  17:1540-1548. 2017
    2017 Prognostic value of serum biomarkers of autoimmunity for recurrence of IGA nephropathy after kidney transplantationJournal of the American Society of Nephrology.  28:1943-1950. 2017
    2017 A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunctionJournal of the American Society of Nephrology.  28:1306-1313. 2017
    2017 GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathwayPLoS Genetics.  13. 2017
    2017 Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathyKidney International.  91:235-243. 2017
    2017 Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA NephropathyKidney International Reports.  2:1194-1207. 2017
    2017 Serial Galactose-Deficient IgA1 Levels in Children with IgA Nephropathy and Healthy ControlsInternational Journal of Nephrology.  2017. 2017
    2016 The origin and activities of IgA1-containing immune complexes in IGA nephropathyFrontiers in Immunology.  7. 2016
    2016 Deceased-donor apolipoprotein L1 renal-risk variants have minimal effects on liver transplant outcomesPLoS One.  11. 2016
    2016 APOL1 genotype and kidney transplantation outcomes from deceased african American donorsTransplantation.  100:194-202. 2016
    2016 Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?Disease Markers.  2016. 2016
    2016 Somatic mutations modulate autoantibodies against galactose-deficient IgA1 in IgA nephropathyJournal of the American Society of Nephrology.  27:3278-3284. 2016
    2016 The MEST score provides earlier risk prediction in lgA nephropathyKidney International.  89:167-175. 2016
    2016 Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic StudyDisease Markers.  2016. 2016
    2015 Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantationKidney International.  88:584-592. 2015
    2015 Current understanding of the role of complement in IgA nephropathyJournal of the American Society of Nephrology.  26:1503-1512. 2015
    2015 Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failureAmerican Journal of Transplantation.  15:1615-1622. 2015
    2015 New Insights into the Pathogenesis of IgA Nephropathy.Kidney Diseases.  1:8-18. 2015
    2015 Should kidney donors be genotyped for APOL1 risk alleles?Kidney International.  87:671-673. 2015
    2015 N-Acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathyNephrology Dialysis Transplantation.  30:234-238. 2015
    2014 Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogensNature Genetics.  46:1187-1196. 2014
    2014 Cellular Signaling and Production of Galactose-Deficient IgA1 in IgA Nephropathy, an Autoimmune DiseaseJournal of Immunology Research.  2014. 2014
    2014 Enzymatic sialylation of IgA1 O-glycans: Implications for studies of IgA nephropathyPLoS One.  9. 2014
    2014 A panel of serum biomarkers differentiates IgA nephropathy from other renal diseasesPLoS One.  9. 2014
    2014 Immune profile of IgA-dominant diffuse proliferative glomerulonephritisClinical Kidney Journal.  7:479-483. 2014
    2014 Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymesJournal of Biological Chemistry.  289:5330-5339. 2014
    2014 End-stage renal disease in African Americans with lupus nephritis is associated with APOL1Arthritis and Rheumatology.  66:390-396. 2014
    2013 Biomarkers in IgA nephropathy: Relationship to pathogenetic hitsExpert Opinion on Medical Diagnostics.  7:615-627. 2013
    2013 Pathogenesis of immunoglobulin A nephropathyCurrent Opinion in Nephrology and Hypertension.  22:287-294. 2013
    2013 IgA nephropathy: Molecular mechanisms of the diseaseAnnual Review of Pathology: Mechanisms of Disease.  8:217-240. 2013
    2013 MEdical progress: IgA nephropathyNew England Journal of Medicine.  368:2402-2414. 2013
    2012 The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathyKidney International.  82:1284-1296. 2012
    2012 Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy.Clinical Nephrology.  78:465-469. 2012
    2012 In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cellsResults in Immunology.  2:166-172. 2012
    2012 Serum galactose-deficient IgA1 level is not associated with proteinuria in children with IgA nephropathyInternational Journal of Nephrology.  2012. 2012
    2012 Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathyJournal of the American Society of Nephrology.  23:1579-1587. 2012
    2012 Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysisPLoS Genetics.  8. 2012
    2012 Reply to "genetic determinants of mycophenolate-related anemia and leukopenia after transplantation"Transplantation.  93. 2012
    2012 Glycosylation of IgA1 and pathogenesis of IgA nephropathy 2012
    2012 Naturally occurring structural isomers in serum IgA1 O -glycosylationJournal of Proteome Research.  11:692-702. 2012
    2012 Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathyClinical Nephrology.  78:465-469. 2012
    2012 Erratum: Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy (Journal of Clinical Investigation (2011) 121, 10 (3991-4002) DOI: 10.1172/JCI45563)Journal of Clinical Investigation.  122:778. 2012
    2011 Membrane-assisted online renaturation for automated microfluidic lectin blottingJournal of the American Chemical Society.  133:19610-19613. 2011
    2011 Sugars and alcohol: IgA-associated renal diseases in alcoholic cirrhosisKidney International.  80:1252-1254. 2011
    2011 APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathyJournal of the American Society of Nephrology.  22:1991-1996. 2011
    2011 IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cellsNephrology Dialysis Transplantation.  26:3451-3457. 2011
    2011 Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathyJournal of Clinical Investigation.  121:3991-4002. 2011
    2011 The pathophysiology of IgA nephropathyJournal of the American Society of Nephrology.  22:1795-1803. 2011
    2011 Aberrant glycosylation of iga1 and anti-glycan antibodies in iga nephropathy: Role of mucosal immune systemAdvances in oto-rhino-laryngology.  72:60-63. 2011
    2011 Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathyClinical Journal of the American Society of Nephrology.  6:1903-1911. 2011
    2011 Validation of the Oxford classification of IgA nephropathyKidney International.  80:310-317. 2011
    2011 Genetic determinants of mycophenolate-related anemia and leukopenia after transplantationTransplantation.  91:309-316. 2011
    2011 Novel polymorphisms associated with tacrolimus trough concentrations: Results from a multicenter kidney transplant consortiumTransplantation.  91:300-308. 2011
    2011 Genome-wide association study identifies susceptibility loci for IgA nephropathyNature Genetics.  43:321-329. 2011
    2011 Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritisKidney International.  80:79-87. 2011
    2010 Clustered O-glycans of IgA1: Defining macro- and microheterogeneity by use of electron capture/transfer dissociationMolecular and Cellular Proteomics.  9:2545-2557. 2010
    2010 Galactose-deficient IgA1 in African Americans with IgA nephropathy: Serum levels and heritabilityClinical Journal of the American Society of Nephrology.  5:2069-2074. 2010
    2010 Genetic studies of IgA nephropathy: Past, present, and futurePediatric Nephrology.  25:2257-2268. 2010
    2010 Recommendations for biomarker identification and qualification in clinical proteomicsScience Translational Medicine.  2. 2010
    2010 Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: A comparative binding study.Biochemistry.  49:5671-5682. 2010
    2010 Glomerulonephritis after hematopoietic cell transplantation: IgA nephropathy with increased excretion of galactose-deficient IgA1Nephrology Dialysis Transplantation.  25:1708-1713. 2010
    2010 Tissue distribution and biological activities of immune complexes are determined by their size and compositionNephrology Dialysis Transplantation.  25:1007. 2010
    2010 Familial IgA nephropathy in southeastern Kentucky.Clinical Nephrology.  73:115-121. 2010
    2010 Naturally occurring human urinary peptides for use in diagnosis of chronic kidney diseaseMolecular and Cellular Proteomics.  9:2424-2437. 2010
    2010 The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adultsKidney International.  77:921-927. 2010
    2009 Application of proteomic analysis to renal disease in the clinic 2009
    2009 Sources of urinary proteins and their analysis by urinary proteomics for the detection of biomarkers of disease 2009
    2009 Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: Data from a single US institutionArthritis and Rheumatism.  60:2757-2766. 2009
    2009 The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibilityKidney International.  76:546-556. 2009
    2009 The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classificationKidney International.  76:534-545. 2009
    2009 Secondary listing for deceased-donor kidney transplantation does not increase likelihood of engraftment at a large transplant center: Brief communicationAmerican Journal of Transplantation.  9:1671-1673. 2009
    2009 Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneityJournal of Clinical Investigation.  119:1668-1677. 2009
    2009 Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexateAmerican Journal of Transplantation.  9:1243-1248. 2009
    2008 CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics 2008
    2008 Urinary proteomics in diabetes and CKDJournal of the American Society of Nephrology.  19:1283-1290. 2008
    2008 Systolic dysfunction portends increased mortality among those waiting for renal transplantJournal of the American Society of Nephrology.  19:1190-1196. 2008
    2008 Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathyJournal of the American Society of Nephrology.  19:1008-1014. 2008
    2008 IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1Journal of Clinical Investigation.  118:629-639. 2008
    2008 Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of iga nephropathyKidney and Blood Pressure Research.  31:29-37. 2008
    2008 IgA Glycosylation and IgA Immune Complexes in the Pathogenesis of IgA NephropathySeminars in Nephrology.  28:78-87. 2008
    2007 Electrophoretic methods for analysis of urinary polypeptides in lgA-associated renal diseasesElectrophoresis.  28:4469-4483. 2007
    2007 Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpuraPediatric Nephrology.  22:2067-2072. 2007
    2007 Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: Implications for IgA nephropathyAnalytical and Bioanalytical Chemistry.  389:1397-1407. 2007
    2007 Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseasesWorld Journal of Urology.  25:467-476. 2007
    2007 High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine 2007
    2007 Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levelsKidney International.  71:1148-1154. 2007
    2007 The genetics of IgA nephropathyNature Reviews Nephrology.  3:325-338. 2007
    2007 IgA nephropathy and henoch-schoenlein purpura nephritis: Aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cellsContributions to Nephrology.  157:134-138. 2007
    2007 IgA nephropathy: A clinical overviewContributions to Nephrology.  157:19-26. 2007
    2007 IgA nephropathy: Characterization of IgG antibodies specific for galactose-deficient IgA1Contributions to Nephrology.  157:129-133. 2007
    2007 IgA nephropathy: Current views of immune complex formationContributions to Nephrology.  157:56-63. 2007
    2007 Identification and Characterization of CMP-NeuAc:GalNAc-IgA1 α2,6-Sialyltransferase in IgA1-producing CellsJournal of Molecular Biology.  369:69-78. 2007
    2007 Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteinsMolecular Immunology.  44:2598-2604. 2007
    2007 Clinical proteomics: A need to define the field and to begin to set adequate standards 2007
    2006 IgA-containing immune complexes in the urine of IgA nephropathy patientsNephrology Dialysis Transplantation.  21:2478-2484. 2006
    2006 Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantationACP journal club.  144:735-741. 2006
    2006 Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group.Clinical Journal of the American Society of Nephrology.  1:467-474. 2006
    2005 Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetilNephrology Dialysis Transplantation.  20:1214-1221. 2005
    2005 IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cellsKidney International.  67:504-513. 2005
    2004 IgA nephropathy: An updateCurrent Opinion in Nephrology and Hypertension.  13:171-179. 2004
    2004 Angiotensin II Receptor Type 1 Expression in Erythroid Progenitors: Implications for the Pathogenesis of Postrenal Transplant ErythrocytosisSeminars in Nephrology.  24:120-130. 2004
    2004 Incidence of hip osteonecrosis among renal transplantation recipients: A prospective studyClinical Radiology.  59:431-438. 2004
    2003 Bone mineral density changes within six months of renal transplantation.Transplantation.  75:49-54. 2003
    2002 Interactions of human mesangial cells with IgA and IgA-containing immune complexesKidney International.  62:465-475. 2002
    2001 Progress in molecular and genetic studies of IgA nephropathyJournal of Clinical Immunology.  21:310-327. 2001
    2001 Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow-upTransplantation.  71:1681-1683. 2001
    2000 IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23Nature Genetics.  26:354-357. 2000
    2000 Treatment of IgA nephropathySeminars in Nephrology.  20:277-285. 2000
    2000 Posttransplant lymphoproliferative disorder localized near the allograft in renal transplantationTransplantation.  69:809-814. 2000
    2000 Focal posttransplantation lymphoproliferative disorder at the renal allograft hilumAmerican Journal of Roentgenology.  175:1417-1422. 2000
    2000 IgA1 glycosylation and the pathogenesis of IgA nephropathyAmerican Journal of Kidney Diseases.  35:551-554. 2000
    1999 Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trialTransplantation.  68:1526-1532. 1999
    1999 Expression of stem cell factor by osteoblasts in normal and hyperparathyroid bone: Relation to ectopic mast cell differentiation 1999
    1999 Parathyroid hormone-regulated production of stem cell factor in human osteoblasts and osteoblast-like cellsBiochemical and Biophysical Research Communications.  255:778-784. 1999
    1999 Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodiesJournal of Clinical Investigation.  104:73-81. 1999
    1999 Progress in the pathogenesis of IgA nephropathy.Advances in nephrology from the Necker Hospital.  29:53-72. 1999
    1999 Treatment of immunoglobulin A nephropathyPresse Médicale.  150:127-136. 1999
    1998 Losartan, an Angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosisJournal of the American Society of Nephrology.  9:1104-1108. 1998
    1998 Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994Journal of the American Society of Nephrology.  9:853-858. 1998
    1998 Late expression of tumor necrosis factor-α is markedly depressed in patients with IgA nephropathy 1998
    1997 Renal transplantation in African-American recipients: three decades at a single center.Transplantation Proceedings.  29:3726-3728. 1997
    1997 Angiotensin II stimulates proliferation of normal early erythroid progenitorsJournal of Clinical Investigation.  100:2310-2314. 1997
    1997 Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgGKidney International.  52:509-516. 1997
    1997 Human peritoneal B-1 cells and the influence of continuous ambulatory peritoneal dialysis on peritoneal and peripheral blood mononuclear cell (PBMC) composition and immunoglobulin levelsClinical and Experimental Immunology.  109:356-361. 1997
    1997 The impact of renal transplantation on survival in hepatitis C- positive end-stage renal disease patientsAmerican Journal of Kidney Diseases.  29:608-614. 1997
    1996 Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: Results of a prospective studyJournal of the American Society of Nephrology.  7:831-835. 1996
    1996 Impact of donor/recipient size matching on outcomes in renal transplantationTransplantation.  61:383-388. 1996
    1996 Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathyKidney International.  49:571-577. 1996
    1996 Benefits of continued cyclosporine through an indigent drug programAmerican Journal of Kidney Diseases.  28:572-577. 1996
    1996 Dilemmas in renal transplantation: When the clinical course and histological findings differAmerican Journal of Kidney Diseases.  27:435-440. 1996
    1996 IgA nephropathy: Defect of glycosylation of IgA1 moleculesJournal of Investigative Medicine.  44. 1996
    1995 Complications of the musculoskeletal system in renal transplant recipientsJournal of Nephrology.  8:231-237. 1995
    1995 IgA nephropathy: A disease of incomplete IgA 1 glycosylation?Advances in Experimental Medicine and Biology.  376:221-222. 1995
    1995 Intraperitoneal administration of tetanus toxoid elicits a specific responses of antibody-secreting cells in the peritoneal cavityAdvances in Experimental Medicine and Biology.  371:103-106. 1995
    1995 Progress in Renal Transplantation a Single Center Study of 3359 Patients over 25 YearsAnnals of Surgery.  221:446-458. 1995
    1994 Hemolytically inactive C4B complement allotype caused by a proline to leucine mutation in the C5-binding siteJournal of Biological Chemistry.  269:27727-27731. 1994
    1994 Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosisKidney International.  46:1397-1403. 1994
    1994 Immunological studies of IgA nephropathy in blacks reveal elevations of serum IgA2 as well as IgA1Nephrology Dialysis Transplantation.  9:1324-1329. 1994
    1994 Intraperitoneal immunization of human subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit a secretory IgA responseClinical and Experimental Immunology.  96:356-363. 1994
    1994 Posttransplant Erythrocytosis: An Enigma RevisitedAmerican Journal of Kidney Diseases.  24:1-11. 1994
    1994 Renal retransplantation: The role of race, quadruple immunosuppression, and the flow cytometry cross-matchTransplantation.  57:47-54. 1994
    1993 Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patientsJournal of the American Society of Nephrology.  3:1570-1574. 1993
    1993 Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial.Contributions to Nephrology.  104:198-206. 1993
    1993 Bone loss after organ transplantationTransplantation Reviews.  7:82-95. 1993
    1993 Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy.Contributions to Nephrology.  104:172-182. 1993
    1993 Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single centerAnnals of Surgery.  217:476-484. 1993
    1993 Immunoglobulin A-Fibronectin Aggregate Levels in Children and Adults With Immunoglobulin A NephropathyAmerican Journal of Kidney Diseases.  22:1-4. 1993
    1993 Metabolic bone disease in renal transplant recipientsEndocrinologist.  3:415-424. 1993
    1993 ReplyAmerican Journal of Kidney Diseases.  21:344. 1993
    1993 Shared idiotypes in mesangial deposits in IgA nephropathy are not disease-specificKidney International.  44:65-74. 1993
    1993 Tapering or Discontinuing Cyclosporine for Financial Reasons—A Single-Center ExperienceAmerican Journal of Kidney Diseases.  21:9-15. 1993
    1992 Benefits of quadruple immunosuppressive therapy in recipients of living related donor kidneys: A review of 855 operationsAnnals of Surgery.  215:606-617. 1992
    1992 Binding of serum immunoglobulins to collagens in IgA nephropathy and HIV infectionKidney International.  42:374-382. 1992
    1992 Cytokine-Induced Immunoglobulin Production in Primary IgA NephropathyAmerican Journal of Kidney Diseases.  20:611-617. 1992
    1992 Familial IgA Nephropathy Associated With Bilateral Sensorineural DeafnessAmerican Journal of Kidney Diseases.  19:592-596. 1992
    1992 IgA-containing immune complexes after challenge with food antigens in patients with IgA nephropathyClinical and Experimental Immunology.  89:315-320. 1992
    1992 Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppressionTransplantation.  53:103-109. 1992
    1992 Musculoskeletal Complications After Renal Transplantation: Pathogenesis and TreatmentAmerican Journal of Kidney Diseases.  19:99-120. 1992
    1992 ReplyAmerican Journal of Kidney Diseases.  20:531. 1992
    1992 The impact of the UNOS mandatory sharing policy on recipients of the black and white races-experience at a single renal transplant centerTransplantation.  53:770-774. 1992
    1991 Rapid loss of vertebral mineral density after renal transplantationNew England Journal of Medicine.  325:544-550. 1991
    1991 Are black living-related renal donors at greater long-term risk of renal complications than white donors?Transplantation Proceedings.  23:1328-1329. 1991
    1991 Analysis of 22 years experience in living-related transplantation at the University of Alabama in Birmingham.Clinical transplants.  179-191. 1991
    1991 C4A deficiency and poor prognosis in patients with IgA nephropathyClinical Nephrology.  36:1-5. 1991
    1991 Effects of enalapril on erythrocytosis after renal transplantationACP journal club.  115:954-955. 1991
    1991 Epstein-Barr virus Transformation of B Lymphocytes From IgA Nephropathy Patients and First-Degree Relatives Results in Increased Immunoglobulin Synthesis not Restricted to IgAAmerican Journal of Kidney Diseases.  17:55-61. 1991
    1991 IgA nephropathy in blacks: Studies of IgA2 allotypes and clinical courseKidney International.  39:1218-1224. 1991
    1991 Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipientsTransplantation.  51:70-75. 1991
    1991 Macroscopic Hematuria and Proteinuria Preceding Renal IgA Deposition in Patients With IgA NephropathyAmerican Journal of Kidney Diseases.  17:472-479. 1991
    1991 OKT3 first-dose reaction: Association with T cell subsets and cytokine releaseKidney International.  39:141-148. 1991
    1991 Role for specific complement phenotypes and deficiencies in the clinical expression of IgA nephropathyAmerican Journal of the Medical Sciences.  301:115-123. 1991
    1991 Selective Elevation of Monomeric IgA1 in IgA Nephropathy Patients With Normal Renal FunctionAmerican Journal of Kidney Diseases.  18:313-319. 1991
    1990 C4B Deficiency in Two Siblings With IgA NephropathyAmerican Journal of Kidney Diseases.  15:66-71. 1990
    1990 Cyclosporine-induced changes in glomerular filtration rate and urea excretionAmerican Journal of Medicine.  88:497-502. 1990
    1990 Cyclosporine-induced changes in glomerular filtration rate and urea excretionAmerican Journal of Medicine.  88:497-502. 1990
    1990 Donor antigen-specific immunosuppression in cadaveric and living-related donor kidney allograft recipients.Clinical transplants.  289-300. 1990
    1990 J chain disease: A novel form of plasma cell dyscrasiaAmerican Journal of Medicine.  88:411-416. 1990
    1990 Regional variation in C4 phenotype in patients with IgA nephropathyJournal of Pediatrics.  116. 1990
    1989 Non-specific mesangial staining with antibodies against cytomegalovirus in immunoglobulin-A nephropathy 1989
    1989 Successful renal allografts in recipients with a positive standard, DTE negative cross-matchTransplantation Proceedings.  21:746-747. 1989
    1989 Successful renal allografts in recipients with crossmatch-positive, dithioerythritol-treated negative sera: Race, transplant history, and HLA-DR1 phenotypeTransplantation.  47:240-245. 1989
    1989 Sustained high panel reactive antibody levels in highly sensitized patients: Significance of continued transfusionsTransplantation Proceedings.  21:771-772. 1989
    1989 Use of cryopreserved donor bone marrow in cadaver kidney allograft recipientsTransplantation.  47:66-71. 1989
    1988 A Comparison of OKT3 Monoclonal Antibody and Corticosteroids in the Treatment of Acute Renal Allograft RejectionAmerican Journal of Kidney Diseases.  11:86-89. 1988
    1988 Activation of Complement in IgA NephropathyAmerican Journal of Kidney Diseases.  12:437-442. 1988
    1988 Bilateral Cavernous Sinus Thrombosis due to MucormycosisJAMA Ophthalmology.  106:1089-1092. 1988
    1988 Early graft loss in cyclosporine A-treated cadaveric renal allograft recipients receiving retransplants against previous mismatched HLA-A, -B, -DR donor antigensTransplantation Proceedings.  20:170-172. 1988
    1988 Familial Clustering and Immunogenetic Aspects of IgA NephropathyAmerican Journal of Kidney Diseases.  12:366-370. 1988
    1988 IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States?American Journal of Medicine.  84:129-132. 1988
    1988 On the mechanism by which chloride corrects metabolic alkalosis in manAmerican Journal of Medicine.  84:449-458. 1988
    1987 Genetic factors in primary IgA nephropathyNephrology Dialysis Transplantation.  2:134-142. 1987
    1987 Morphologic and immunohistochemical observations in granulomatous glomerulonephritisAmerican Journal of Pathology.  126:581-591. 1987
    1987 A major gene model for the familial aggregation of plasma IgA concentrationAmerican Journal of Medical Genetics Part A.  27:857-866. 1987
    1987 Aberrant synthesis of antibodies directed at the Fab fragment of IgA in patients with IgA nephropathiesClinical Immunology.  45:208-213. 1987
    1987 Analysis of immunoglobulin heavy chain restriction fragment length polymorphisms in IgA nephropathy.Seminars in Nephrology.  7:306-310. 1987
    1987 Antibodies directed at Fab of IgA in the sera of normal individuals and IgA nephropathy patients.Advances in Experimental Medicine and Biology.  216 B:1537-1544. 1987
    1987 Complement activation in IgA nephropathyKidney International.  31:1019-1023. 1987
    1987 Complement phenotypes (C3 and C4) in IgA nephropathy.Advances in Experimental Medicine and Biology.  216 B:1569-1575. 1987
    1987 Detection of food antigen-specific IgA immune complexes in human sera.Advances in Experimental Medicine and Biology.  216 A:813-820. 1987
    1987 Fatal rhizopus infections in hemodialysis patients receiving deferoxamineACP journal club.  107:678-679. 1987
    1987 IgA-associated renal diseases: immunochemical studies of IgA1 proteins, circulating immune complexes, and cellular interactions.Seminars in Nephrology.  7:332-335. 1987
    1987 Immunogenetic markers as prognostic features in patients from Kentucky with IgA nephropathy.Seminars in Nephrology.  7:389-392. 1987
    1987 Immunological studies of IgA nephropathy: familial and racial aspects.Advances in Experimental Medicine and Biology.  216 B:1489-1498. 1987
    1987 Influence of race on renal allograft survival in the pre- and postcyclosporine era.Clinical transplants.  217-233. 1987
    1987 Oxalosis in Bone Causing a Radiographical Mimicry of Renal OsteodystrophyAmerican Journal of Kidney Diseases.  9:436-440. 1987
    1987 Regionalization in hereditary IgA nephropathyAmerican Journal of Human Genetics.  41:36-50. 1987
    1987 Striking Elevation of Serum IgA, IgA-Containing Immune Complexes, and IgA Rheumatoid Factor in Clinically Silent Dermatitis HerpetiformisAmerican Journal of Kidney Diseases.  10:378-384. 1987
    1986 Aluminum-associated renal osteodystrophy.The Alabama journal of medical sciences.  23:414-419. 1986
    1986 Aluminum-related bone disease in mild and advanced renal failure: Evidence for high prevalence and morbidity and studies on etiology and diagnosisAmerican Journal of Nephrology.  6:275-283. 1986
    1986 Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathiesJournal of Clinical Investigation.  77:1931-1938. 1986
    1986 IgA-associated renal diseases: Antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruliJournal of Clinical Immunology.  6:74-86. 1986
    1985 Familial IgA NephropathyNew England Journal of Medicine.  313:186. 1985
    1985 Familial IgA Nephropathy: Evidence of an Inherited Mechanism of DiseaseNew England Journal of Medicine.  312:202-208. 1985
    1985 Focal Sclerosis of Hypertrophied Glomeruli in Solitary Functioning Kidneys of HumansAmerican Journal of Kidney Diseases.  5:226-232. 1985
    1985 The immunogenetics of IgA nephropathyPlasma Therapy and Transfusion Technology.  6:687-704. 1985
    1984 Complement phenotypes in glomerulonephritis: Increased frequency of homozygous null C4 phenotypes in IgA nephropathy and Henoch-Schonlein purpuraKidney International.  26:855-860. 1984
    1984 IgA Nephropathy: Presentation, Clinical Course, and Prognosis in Children and AdultsAmerican Journal of Kidney Diseases.  4:192-200. 1984
    1984 Increased frequency of C3 fast alleles in IgA nephropathyDisease Markers.  2:419-428. 1984
    1983 Serum complement proteins in IgA nephropathyClinical Nephrology.  20:251-258. 1983
    1982 Partial H (β1H) deficiency and glomerulonephritis in two familiesJournal of Clinical Immunology.  2:110-117. 1982
    1982 Renin and aldosterone responses to short-term NaCl or NaHCO3 loading in man 1982
    1981 Properdin Deficiency with IgA NephropathyNew England Journal of Medicine.  305:1097. 1981


    Year Title Altmetric
    2016 Heterogeneity of aberrant O-glycosylation of IgA1 in IgA nephropathy.  53-68. 2016
    2015 IgA Nephropathy and Related Diseases.  2023-2038. 2015
    2009 Clinicopathologic findings.  83-106. 2009

    Research Overview

  • IgA nephropathy
    Kidney transplantation
  • Investigator On

  • A Trial of Transplanting Hepatitis C-Viremic Kidneys Into Hepatitis C-Negative Kidney Recipients (THINKER-NEXT) Cost-Reimbursement  awarded by University of Pennsylvania
  • A Trial of Transplanting Hepatitis C-viremic Kidneys into Hepatitis C-Negative Kidney Recipients (THINKER-NEXT) Fixed Rate  awarded by University of Pennsylvania
  • APOL1 Long-Term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • APOL1 Long-term kidney Transplantation Outcomes Network (APOLLO) Clinical Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Abnormal STAT3 Signaling and Aberrant O-Glycosylation of IgA1 in IgA Nephropathy  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Analytical Tools for the Analysis of Clustered O-Glycans in Clinical Samples  awarded by National Institute of General Medical Sciences/NIH/DHHS
  • Analytical Tools for the Analysis of Clustered O-Glycans in Clinical Samples  awarded by National Institute of General Medical Sciences/NIH/DHHS
  • Applying Precision MEdicine to Optimize Desensitization with NoveL BIOlogics or Cellular TheRApies in Highly SensiTized Kidney Transplant PatiEnts (AMELIORATE)  awarded by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
  • Aptamers-Based Arrays for Detection of Pathogenic IgA 1 O-Glycoforms in IgA Nephropathy  awarded by Columbia University
  • Cure GN 2.0 - UNC-PCC  awarded by University of North Carolina
  • CureGN-2: UNCPCC (Cost Reimbursement)  awarded by University of North Carolina at Chapel Hill
  • Distinct Glycophenotypes and Abnormal Signaling Define a Subpopulation of B cells Responsible for Production of Autoantigen in IgA Nephropathy  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Effects of Inhibiting Early Inflammation in Kidney Transplant Patients  awarded by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
  • Effects of Inhibiting Early Inflammation in Kidney Transplant Patients - Equipment  awarded by Mount Sinai School of Medicine ^
  • Elucidating IgA Nephropathy Through Genetic Studies of IgA1 Glycosylation  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Elucidating IgA Nephropathy Through Genetic Studies of IgA1 Glycosylation  awarded by Columbia University
  • Elucidating lgA Nephropathy through Genetic Studies of lgA 1 Glycosylation  awarded by Columbia University
  • Genetic, Environmental & Histologic Basis for Kidney Disease Risk among Persons Living with HIV  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Genetic, Environmental & Histologic Basis for Kidney Disease Risk among Persons Living with HIV  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Genetics of IgA Nephropathy by Integrative Network-Based Association Studies  awarded by Columbia University
  • IgA Nephropathy: Interventions with Generation of Nephritogenic Immune Complexes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Molecular Basis of Pathogenicity of IgA1-Containing Immune Complexes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Molecular Basis of Pathogenicity of IgA1-containing Immune Complexes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • New Animal Model for Studies of Mucosal Immunity and IgA Nephropathy  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts  awarded by University of California, San Francisco
  • Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts  awarded by University of California, San Francisco
  • Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Preserving Renal Function & Protective Immunity via Anti-LFA-1-Based CNI Avoidance  awarded by Emory University
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by ANTHERA PHARMACEUTICALS, INC
  • Private Grant  awarded by ALEXION PHARMACEUTICALS, INC.
  • Private Grant  awarded by QUARK PHARMACEUTICALS, INC.
  • Private Grant  awarded by MALLINCKRODT, INC.
  • Private Grant  awarded by CSL BEHRING, LLC
  • Private Grant  awarded by VELOXIS PHARMACEUTICALS A/S
  • Private Grant  awarded by CALLIDITAS THERAPEUTICS AB
  • Private Grant  awarded by ALEXION PHARMACEUTICALS, INC.
  • Private Grant  awarded by RETROPHIN, INC.
  • Private Grant  awarded by CSL BEHRING, LLC
  • Private Grant  awarded by VISTERRA, INC
  • Private Grant  awarded by NATERA, INC.
  • Private Grant  awarded by CSL BEHRING, LLC
  • Private Grant  awarded by MALLINCKRODT, INC.
  • Private Grant  awarded by CAREDX INC.
  • Private Grant  awarded by TRANSPLANT GENOMICS, INC.
  • Private Grant  awarded by CHINOOK THERAPEUTICS, INC
  • The Impact of Diabetes on Patients with Glomerular Disease: CureGN-Diabetes (CR)  awarded by University of North Carolina at Chapel Hill
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Education And Training

  • University of Kentucky/Chandler Hospital, Internship
  • University of Kentucky/Chandler Hospital, Residency
  • University of Kentucky/Chandler Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, Washington University/St. Louis 1975
  • Full Name

  • Bruce Julian